Biological Agents in the Treatment of Rheumatoid Arthritis

SM KAMAL a, MA BAKAR b

Introduction:
Rheumatoid arthritis is a chronic inflammatory disease. Established treatment is limited because of the unsatisfactory clinical response or the development of unexpected adverse events with the drugs used. In recent years intensive research into the pathogenesis of RA has yielded information which permits clear insights into the mechanism of the underlying disease. Inflammatory cells produce a number of cytokines, which play a role in inflammation leading to damage to the bone and cartilage. These findings finally led to the development of biological agents for the treatment of rheumatoid arthritis. These agents target cytokines such as tumour necrosis factor-alpha (TNF-a), interleukin-1 (IL-1), interleukin-6 (IL-6) or cell surface molecules such as (CD4, CD5, CD7, IL-2 receptor, CDw52 or CD54). New biological agents evaluated for treatment of RA have shown much success in different clinical trails. RA is no longer considered a benign disease. Statistical analysis has shown increased mortality in patients with RA compared with average population.

Biological agents are recommended for the treatment of rheumatoid arthritis, juvenile chronic arthritis, still’s disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, castleman’s disease, B-cell lymphoma, crohn’s disease, vasculitis (refractory wegener’s granulomatosis, life threatening Behcets disease).

This review article will give a short overview on the various biological agents recommended in the therapy of rheumatoid arthritis (RA).

Pathogenesis of Rheumatoid Arthritis
Rheumatoid arthritis (RA) is characterised by persistent inflammatory synovitis. It predominantly affects the peripheral joints. Exact aetiology of RA is not known. Different research works suggest that RA is caused by an unidentified arthritogenic antigen. The antigen could be either exogenous such as viral or bacterial protein or endogenous such as human cartilage glycoprotein 39 or heavy chain-binding protein.

Antigen-activated CD4+ T-cells stimulate monocytes, macrophages and synovial fibroblasts to produce various cytokines. Tumour necrosis factor - alpha (TNF-a), interleukin - 1 (IL-1) and interleukin-6 (IL-6) are the key cytokines that drive inflammation in RA and cause...
joint damage. They are potent stimulators of synovial fibroblasts, osteoclasts and chondrocytes that release tissue destroying matrix metalloproteinases (MMP), which contribute to joint damage. Activated CD4+ T-cells also stimulate B cells to produce immunoglobulins including rheumatoid factor (RF). RF may involve the activation of complement through the formation of immune complex. The products of activated macrophages, lymphocytes and fibroblasts stimulate angiogenesis. Inflammatory cells are recruited into the joint by expression of adhesion molecules in endothelial cells in the synovium. This leads to the formation of hyperplastic, proliferating, inflamed synovium also called “Pannus”. Activated macrophages and synovial fibroblasts are present in the interface between the Pannus and cartilage causing damage to the joint. There occurs progressive erosion of subchondral bone with Juxta-articular osteopenia. Destruction of bone and cartilage occurs progressively leading to significant disability.

Radiological evidence of substantial joint damage is seen within 2 years of disease onset. Evidence of bone erosion is seen within first-few months by magnetic resonance imaging (MRI). Osteoporosis due to reduced bone mineral density increases the risk of bone fracture. Recent study have shown that 80% of patients with RA are disabled within 10 years and survival is reduced.

Indications and clinical considerations of biological agents

Biological agents are used in the management of Rheumatoid Arthritis (RA). Juvenile idiopathic arthritis (JIA), still’s disease, ankylosing spondylitis, psoriasis, Psoriatic arthritis, crohn’s disease, vasculitis (Refractory wegener’s granulomatosis and Behcet’s disease).

The onset of action is rapid and occurs within 2 to 4 weeks. Infliximab can not be used as monotherapy and has to be combined with methotrexate. Other agents can be used alone or in combination with methotrexate. Cytokine antagonists should be withdrawn in the face of adverse events or lack of adequate response. If one TNF-a blocker fails, substitution with another agent may be helpful. Cardiovascular disease is the major cause of increased mortality in RA due to accelerated atherosclerosis. Cytokine antagonists have shown a favourable response in endothelial cell dysfunction in these patients.

Classification and mode of action of biological agents

Functionally biological agents can be divided into three classes.

1. Interfere cytokine function

   a) Anti-tumour necrosis factor-alpha (Anti-TNF-α)
     Infliximab, Etanercept, Adalimumab
   b) Anti-interleukin-1 (Anti-IL-1)
     Anakinra
   c) Anti-interleukin-6 (Anti-IL-6)
     Tocilizumab

There are three types of anti-cytokine molecules:

   i) Soluble receptor antagonist - Etanercept
   ii) Monoclonal antibodies (mAb) to cytokines or to their receptors
     Infliximab, Adalimumab, certalizumab
   iii) Cell surface receptor antagonist protein: Anakinra, Tocilizumab.

2. Inhibit the “Second signal” required for T-cell activation, the co-stimulation blocker, Abatacept.

3. B cell depletion – Rituximab

Dosage, administration, side effects and contraindications of a few biological agents used in the treatment of rheumatoid arthritis

Infliximab (remicade)

3mg/kg i.v infusion at weeks 0, 2 and 6 followed by maintenance dose every 8 weeks. Has to be combined with methotrexate.

Side effects – Infusion reaction (Fever, chills, urticaria, chest pain, dyspnoea, hypotension), antibody formation,
infection, upper respiratory infection, reactivation of tuberculosis (TB), exacerbation of demyelinating disease.

contraindications – Active infection, uncontrolled diabetes mellitus, surgery (withhold for 2 weeks post-operatively)23,24,25.

Etanercept (enbrel)
25 mg subcutaneously twice a week or 50mg once a week. May be given with MTX or as monotherapy.

Side effects – Injection site reactions, upper respiratory infection, development of anti-nuclear antibody (ANA), infection, reactivation of TB, exacerbation of demyelinating disease.

Contraindications – Active infection, uncontrolled DM, Surgery (withhold for 2 weeks post operatively)26,27.

Adalimumab (humira)
40 mg subcutaneously every 2 weeks. May be given with MTX or as monotherapy.

Side effects – upper respiratory infection, injection site pain, rash, headache, sinusitis, infection, exacerbation of demyelinating disease.

Contraindications – Active infection 26,27.

Anakinra (kinaret)
100 mg subcutaneously once daily. May be given with MTX or as monotherapy.

Side effects – Injection site reaction, infection, neutropenia.

Contraindications – active infection28.

Tocilizumab
8gm/kg subcutaneously every four weeks29.

Safety Issues in Biological Agent Therapy
The cytokines play an important role in protective immunity. The risk of infection increases with the use of anti-cytokines30. Reactivation of tuberculosis occurs mostly with infliximab. Opportunistic infection and lymphoma has been reported with the use of TNF-a antagonists31,32. Demyelinating disorders may occur by therapy with all biological agents except anakinra (IL-1 receptor antagonist). Active or recent history of malignancy except skin cancer. Relative contraindications are pregnancy, lactation, HIV, HBV and HCV infection36.

Monitoring during therapy with biologics
Clinicians should be aware of potential treatment related adverse effects and monitor the patient accordingly. Most important adverse effects of anti TNF-a therapy is increased risk of severe infections due to blockade of pro-inflammatory cytokines. The half life of biological agents become relevant. Adalimumab has long half life of 2 weeks and produce a longer period of immunosuppresion with risk of infection per dose. Care should be taken for diabetic patients. Cutaneous injection site reaction consists of local erythema and swelling which usually subsides within 24 hours. It can be lessened by predosing with antihistamine. Intravenous infusion reactions are fever, chills and nausea. These can also be prevented by premedication37.

Impact of biological agents in current clinical practice
Biological response modifiers represent advancement in the treatment of RA. Disease activity can be well controlled and joint function improves almost to normal. There are still some non-responders and newer agents address some of these needs38.

Future trends of biological agents
Anti- TNF-a preparations that are given as monthly subcutaneous injections are currently being developed38.

Conclusions:
The availability of biological agents that target specific cytokines involved in the joint destruction will raise the
new era in the treatment of RA. The major hindrance to the use of cytokine antagonists is their cost. Epidemiological studies will be needed to document the long term benefits and risks associated with the cytokines.

References:
11. Abramson SB, Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology 2002; 41: 972-980.


